10.21
前日終値:
$10.55
開ける:
$10.63
24時間の取引高:
421.33K
Relative Volume:
0.59
時価総額:
$354.29M
収益:
$2.07M
当期純損益:
$-47.68M
株価収益率:
-3.6206
EPS:
-2.82
ネットキャッシュフロー:
$-31.31M
1週間 パフォーマンス:
+0.20%
1か月 パフォーマンス:
-0.87%
6か月 パフォーマンス:
-10.52%
1年 パフォーマンス:
-33.92%
Delcath Systems Inc Stock (DCTH) Company Profile
名前
Delcath Systems Inc
セクター
電話
(518) 743-8892
住所
566 QUEENSBURY AVENUE, QUEENSBURY, NY
DCTH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
DCTH
Delcath Systems Inc
|
10.21 | 366.09M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-28 | 開始されました | Craig Hallum | Buy |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2022-07-26 | 再開されました | Canaccord Genuity | Buy |
| 2021-12-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-09 | 開始されました | Canaccord Genuity | Buy |
| 2021-01-05 | 開始されました | BTIG Research | Buy |
| 2020-06-01 | 開始されました | Laidlaw | Buy |
すべてを表示
Delcath Systems Inc (DCTH) 最新ニュース
Liver cancer-focused Delcath joins BTIG MedTech, digital health conference - Stock Titan
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Yahoo Finance
(DCTH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Analysis Recap: Is CYCCP forming a double bottomMarket Growth Report & Real-Time Market Sentiment Reports - baoquankhu1.vn
Shorts Report: Is GIGGU backed by strong institutional buyingJuly 2025 Technicals & Technical Buy Zone Confirmation - baoquankhu1.vn
Returns On Capital Are Showing Encouraging Signs At Delcath Systems (NASDAQ:DCTH) - Yahoo Finance
Delcath Systems, Inc. (DCTH) Stock Analysis: A 103% Upside Potential In Medical Devices - DirectorsTalk Interviews
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 21, 2026 - BioSpace
Delcath Systems, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Is Delcath Systems Inc backed by strong institutional buyingLong Setup & Daily Growth Stock Investment Tips - baoquankhu1.vn
Market Catalysts: Is ODYS forming a bullish divergenceEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Price-Driven Insight from (DCTH) for Rule-Based Strategy - Stock Traders Daily
Delcath Systems expects FY revenue of $85.2 million - MSN
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems Reports Strong Preliminary 2025 Results - TipRanks
NY-based Delcath Systems expects Q4 2025 revenue to hit USD 20.7M - Medical Buyer
Aug Closing: Is Delcath Systems Inc subject to activist investor interestJuly 2025 Institutional & Target Return Focused Stock Picks - baoquankhu1.vn
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2025 Earnings Call Transcript - MSN
EBITDA per share of Delcath Systems, Inc. – DUS:DV3R - TradingView — Track All Markets
Delcath reports $85.2 million in 2025 revenue, strong cash position By Investing.com - Investing.com Nigeria
Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
DCTH FinancialsIncome Statement - Quiver Quantitative
DCTH: HC Wainwright Reiterates Buy Rating with $30 Price Target - GuruFocus
HC Wainwright Reaffirms Buy Rating for Delcath Systems (NASDAQ:DCTH) - MarketBeat
Delcath Systems, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 - MarketScreener
Delcath Systems (DCTH) Exceeds Revenue Expectations in Q4 and Fu - GuruFocus
Delcath Systems announces preliminary fourth quarter and full year 2025 financial results - marketscreener.com
Delcath reports $85.2 million in 2025 revenue, strong cash position - Investing.com
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The AI Journal
Will Delcath Systems Inc. stock outperform Nasdaq indexWeekly Market Report & Fast Entry Momentum Alerts - ulpravda.ru
Delcath Systems Announces Preliminary Fourth Quarter And Full Year 2025 Financial Results - TradingView
ETF Watch: Will Delcath Systems Inc. stock remain a Wall Street favoriteTrade Ideas & Reliable Price Breakout Signals - Улправда
How resilient is Delcath Systems Inc. stock in market downturnsJuly 2025 Retail & Weekly Top Gainers Alerts - ulpravda.ru
Will Delcath Systems Inc. stock remain a Wall Street favoriteMarket Volume Summary & Daily Technical Forecast Reports - Улправда
Shorts Report: Will Delcath Systems Inc stock remain a Wall Street favorite2025 Earnings Impact & Daily Growth Stock Investment Tips - Bộ Nội Vụ
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates - MSN
A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT - Sahm
Under the Radar: 3 Microcap Growers Passing a Tough Test - Benzinga
Will Delcath Systems Inc. stock sustain high P E ratios2026 world cup usa national team round of 16 key players high defensive line match prediction expert opinion - Улправда
Will New HEPZATO KIT Subgroup Data on Tumor Burden and Survival Change Delcath Systems' (DCTH) Narrative - Sahm
(DCTH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Should New HEPZATO Subgroup Data and Delcath’s Targeted Strategy Require Action From DCTH Investors? - Yahoo Finance
Are options traders betting on a big move in Delcath Systems stock? - MSN
Delcath Systems Inc Stock Analysis and ForecastLong-Term Growth Stocks & Fast Growing Investment Plans - earlytimes.in
Hepzato Kit Safe, Effective in Metastatic, Unresectable Uveal Melanoma - Cure Today
Are Options Traders Betting on a Big Move in Delcath Systems Stock? - Nasdaq
Delcath Systems publishes results from subgroup analyses of FOCUS study - Yahoo Finance
Delcath’s HEPZATO shows consistent efficacy across patient subgroups By Investing.com - Investing.com Nigeria
Delcath Systems (DCTH) Reveals Key Findings from FOCUS Study Sub - GuruFocus
Delcath Systems Inc (DCTH) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):